Supplementary Data — Cetylpyridinium Chloride reduces COVID-19 risk: real-time meta analysis of 4 studies

@CovidAnalysis, November 2025, Version 6V6
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Bonn (DB RCT) 85% 0.15 [0.01-2.74] viral load 6 (n) 9 (n) Short term viral CT​1​ Improvement, RR [CI] Treatment Control AMPoL Gansky (DB RCT) 60% 0.40 [0.02-7.68] no recov. 0/3 1/6 Ponphaib.. (DB RCT) 36% 0.64 [0.46-0.89] no recov. 25/53 42/57 CT​1​ Ponphaib.. (DB RCT) 24% 0.76 [0.64-0.89] no recov. 43/59 55/57 CT​1​ Ponphaib.. (DB RCT) 14% 0.86 [0.77-0.97] no recov. 50/59 56/57 CT​1​ Ponphaib.. (DB RCT) 30% 0.70 [0.59-0.84] no recov. 40/59 55/57 CT​1​ Rengifo (DB RCT) 68% 0.32 [0.01-7.20] hosp. 0/12 1/11 CT​1​ Rengifo (DB RCT) 83% 0.17 [0.02-1.20] viral+ 1/12 5/10 CT​1​ Cetylpyridinium chloride COVID-19 outcomes c19early.org November 2025 ​1​ CT: study uses combined treatment Favors CPC Favors control
Fig. S1. All outcomes.